Status:
UNKNOWN
Study on the Mechanism of Prevotella Copri Promoting the Occurrence and Development of Atherosclerosis
Lead Sponsor:
Hai Tian
Conditions:
Atherosclerosis
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Mainly studying the correlation between the abundance of Prevotella copri （P.copri） in the gut microbiome and the progression of clinical coronary atherosclerotic heart disease（CAD） patients, and conf...
Detailed Description
Confirming the progression of coronary heart disease in patients and the proportion of P.copri in the gut microbiome; Confirming that due to the increased abundance of P.copri, factors related to bloo...
Eligibility Criteria
Inclusion
- Atherosclerosis mechanism research: diagnosis is made through clinical diagnostic technical indicators, mainly coronary CT or coronary angiography. Experimental group: patients with coronary heart disease are identified; Control group: Admitted patients without coronary heart disease but may have other heart diseases or risk factors; Age:\>50 years old
- KAP Study: Coronary Heart Disease Patients and Their Families
Exclusion
- Atherosclerosis mechanism research: age\<50 years old; Patients with a history of coronary heart disease or surgery; Patients with systemic diseases, including liver and kidney diseases (with serum creatinine levels\>2mg/dL (176.8 μ Mol/dL), collagen diseases, etc; Patients who have been using antibiotics within the past 6 months; Patients with malignant tumor disease
- KAP Study: Non coronary heart disease patients and their caregivers
Key Trial Info
Start Date :
August 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 7 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06047249
Start Date
August 23 2022
End Date
July 7 2024
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150086